載入中
NASDAQHealthcareBiotechnology
最新資料
US$18.15
+US$0.24 · +1.34%
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
前收盤價
US$18.15
+US$0.24 · +1.34%
盤中時間採用ET。市場資料可能有所延遲。
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
日內區間
目前US$18.15
52週區間
目前US$18.15
盤中時間採用ET。市場資料可能有所延遲。
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
日內區間
目前US$18.15
52週區間
目前US$18.15
| 項目（USD） | 2025會計年度 |
|---|---|
| 研究與開發 | 6631.3萬 USD |
| 銷售、一般及管理費用 | 2098.1萬 USD |
| 營業費用 | 8729.4萬 USD |
| 利息收入 | 1140.3萬 USD |
| 折舊和攤銷 | 140.5萬 USD |
| 營業利益 | −8729.4萬 USD |
| 淨利 | −7488.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1009.65萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM646.75萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF396.79萬0.00%954億 USD0.05%US$235+0.80%
AdvisorShares Psychedelics ETFPSIL158.51萬3.38%4685.29萬 USD1.84%US$21.765+3.69%
Schwab U.S. Small-Cap ETFSCHA139.02萬0.01%218.24億 USD0.03%US$32.79+0.40%
iShares Russell 2000 Growth ETFIWO138.35萬0.01%139.17億 USD0.24%US$356.78+0.94%
ALPS Medical Breakthroughs ETFSBIO123.4萬0.64%1.91億 USD0.50%US$55.04+2.03%
iShares Micro-Cap ETFIWC80.32萬0.06%13.17億 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFAdvisorShares Psychedelics ETFPSILSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
